Active Recombinant Human FLT1 Protein, His-Avi-tagged, Biotinylated

• Cat.No.: FLT1-3810H
• Product Overview: Biotinylated Human VEGF R1, His Tag, Avi Tag is expressed from HEK293 cells. It contains AA Ser 27 - Asn 756 (Accession # P17948-1). This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag.

Specification

• Source: HEK293
• Species: Human
• Tag: His&Avi
• Predicted N Terminal: Ser 27
• Form: Lyophilized from 0.22 um filtered solution in PBS, pH7.4, 10% trehalose.
• Bio-activity: Immobilized Human VEGF165, Tag Free at 2 ug/mL (100 uL/well) can bind Biotinylated Human VEGF R1, His Tag, Avi Tag with a linear range of 1-31 ug/mL. Immobilized Human PLGF, His Tag at 1 ug/mL (100 uL/well) can bind Biotinylated Human VEGF R1, His Tag, Avi Tag with a linear range of 2-20 ug/mL.
• Molecular Mass: The protein has a calculated MW of 85.9 kDa. The protein migrates as 106-125 kDa under reducing condition (SDS-PAGE) due to glycosylation.
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method.
• Purity: >95% as determined by SDS-PAGE..
• Characteristic: Biotinylation of this product is performed using Avitag technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
• Stability: Samples are stable for up to twelve months from date of receipt at -70ºC.
• Storage: For long term storage, the product should be stored at lyophilized state at -20ºC or lower. Please avoid repeated freeze-thaw cycles. No activity loss is observed after storage at: 4-8ºC for 12 months in lyophilized state; -70ºC for 3 months under sterile conditions after reconstitution.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4℃ before opening to recover the entire contents.
• Protein length: Ser27-Asn756

Gene Information

• Gene Name: FLT1 fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor) [ Homo sapiens ]
• Official Symbol: FLT1
• Synonyms: FLT1; fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor); FLT; vascular endothelial growth factor receptor 1; VEGFR1; FLT-1; VEGFR-1; fms-like tyrosine kinase 1; tyrosine-protein kinase FRT; tyrosine-protein kinase receptor FLT; vascular permeability factor receptor
• Gene ID: 2321
• mRNA Refseq: NM_001159920
• Protein Refseq: NP_001153392
• MIM: 165070
• UniProt ID: P17948

Reviews

07/08/2019

the FLT1 protein is an excellent choice for researchers due to its high quality, reliability, and the comprehensive technical support provided by the manufacturer.

07/17/2018

The manufacturer of FLT1 protein provides excellent technical support, ensuring that researchers receive prompt assistance and guidance when encountering any challenges or difficulties.

05/27/2016

Researchers can confidently incorporate FLT1 protein into their experiments, knowing that they have access to a reliable resource that will meet their experimental needs effectively.

Q&As

How is FLT1 linked to preeclampsia in pregnancy?

Elevated levels of soluble FLT1 have been associated with preeclampsia, a pregnancy complication. Soluble FLT1 acts as a decoy receptor, reducing the bioavailability of VEGF and contributing to vascular dysfunction.

How does FLT1 contribute to retinal diseases such as diabetic retinopathy?

FLT1 has been implicated in retinal diseases like diabetic retinopathy, where abnormal blood vessel growth can lead to vision impairment. Inhibiting FLT1 may help regulate angiogenesis in such conditions.

How is FLT1 expression regulated in the human body?

FLT1 expression is regulated by various factors, including VEGF itself, as well as hypoxia and inflammation. These factors influence the balance of angiogenic signaling.

Can FLT1 be a biomarker for certain diseases?

Yes, elevated levels of soluble FLT1 have been investigated as potential biomarkers for conditions like preeclampsia, cancer, and certain cardiovascular diseases.

Can FLT1 be targeted for anti-angiogenic therapy?

Yes, targeting FLT1 is a strategy for anti-angiogenic therapy. Inhibiting FLT1 can impede blood vessel formation, limiting the blood supply to tumors and potentially slowing their growth.